April 20, 2022
BANGKOK — HOYA Vision Care will present findings from its six-year clinical trial on MiYOSMART spectacle lenses at the upcoming ARVO 2022 in Denver, Colo., May 1-4. Professor Carly Lam from the Centre for Myopia Research at the Hong Kong Polytechnic University will present the results, which will include data from children who have worn the MiYOSMART spectacle lens with the Defocus Incorporated Multiple Segments (D.I.M.S.) technology.
This information will enhance a previous three-year follow-up study,1 a continuation of a two-year randomized control trial (RCT),2 which was published in the British Journal of Ophthalmology and that demonstrated strong evidence of the lenses’ effectiveness in slowing down the progression of myopia in children ages 8-13.1
“This six-year clinical study on the MiYOSMART lens is the longest running study conducted on a myopia management spectacle lens ever, a fact we are very proud of,” said Natalia Vlasak, Ophthalmologist, Global Head of Medical and Scientific Affairs at HOYA Vision Care. “Long-term clinical data is essential for evaluating the effectiveness and safety as well as determining possible long-term risks of treatments that can’t be observed during a short period.”
1 Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi:10.1136/bjophthalmol-2020-317664
2 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. Doi: 10.1136/bjophthalmol-2018-313739
PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and it is not currently available for sale in all countries, including the U.S.